Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.

The FDA has approved Merilog, the first-ever rapid-acting insulin biosimilar for diabetes treatment that helps manage blood ...

The regulatory action makes Merilog the first rapid-acting insulin biosimilar to gain FDA approval. According to the federal agency, the approval includes both a prefilled pen and a multi-dose vial, ...

The approval is for both a 3 milliliter or mL single-patient-use prefilled pen and a 10 mL multiple-dose vial. As a rapid-acting human insulin, Merilog helps to lower mealtime blood sugar spikes ...

As a rapid-acting insulin, Merilog helps to lower mealtime blood sugar spikes to improve control of blood sugar in people with diabetes. The approval is for both a 3 milliliter (mL) single-patient-use ...

dosage and administration, cost, and place in therapy of insulin detemir are reviewed. Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject ...

Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin that is Lilly’s top selling drug, bringing in almost $700 ...

Thus, human NPH as part of a multiple injection regimen should be used for intermediate-acting insulin effect in GDM. [14] At present there are no data on the use of detemir in pregnancy.

As a rapid-acting insulin, Merilog helps to lower mealtime blood sugar spikes to improve control of blood sugar in people with diabetes. The approval is for both a 3 milliliter (mL) single-patient-use ...